India Glycols Limited (IGL) has achieved a significant milestone by receiving the Establishment Inspection Report (EIR) with no observations from the U.S. Food and Drug Administration (USFDA) on April 24, 2025. This recognition is for the company’s nutraceutical products and dietary supplement ingredients manufactured at its Dehradun plant.
The EIR from the USFDA is a crucial step in affirming IGL’s adherence to stringent international quality standards. With no observations, the company has demonstrated its commitment to producing high-quality nutraceutical products, which meet the rigorous regulatory requirements of the U.S. market. This opens new avenues for IGL to expand its presence in the premium U.S. market and other highly regulated global markets.
India Glycols has established itself as a key player in the nutraceutical sector, offering a wide range of products that cater to growing global consumer demand for natural and effective supplements. The receipt of the EIR enhances the company’s credibility and strengthens its position in the competitive landscape of nutraceuticals and dietary supplements.
With this accomplishment, India Glycols is poised for further growth and continues to focus on providing innovative, safe, and effective solutions to its customers worldwide.
